Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Your doctor will help you decide which form, pill or injection, of Wegovy is best for you. It may depend on your medical history, which dosing schedule fits your lifestyle better, and how comfortable ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

Downside to dropping pounds? The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved an oral pill form of Wegovy — a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight loss. Until now, ...